- Home
- XNET vs ATAI Comparison
XNET vs ATAI Comparison
Compare XNET & ATAI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- XNET
- ATAI
- Stock Information
- Founded
- XNET 2003
- ATAI 2018
- Country
- XNET China
- ATAI Germany
- Employees
- XNET N/A
- ATAI N/A
- Industry
- XNET Computer Software: Prepackaged Software
- ATAI Biotechnology: Pharmaceutical Preparations
- Sector
- XNET Technology
- ATAI Health Care
- Exchange
- XNET Nasdaq
- ATAI Nasdaq
- Market Cap
- XNET 276.3M
- ATAI 282.6M
- IPO Year
- XNET 2014
- ATAI 2021
- Fundamental
- Price
- XNET $4.40
- ATAI $1.41
- Analyst Decision
- XNET
- ATAI Strong Buy
- Analyst Count
- XNET 0
- ATAI 3
- Target Price
- XNET N/A
- ATAI $10.50
- AVG Volume (30 Days)
- XNET 384.1K
- ATAI 1.4M
- Earning Date
- XNET 05-15-2025
- ATAI 05-19-2025
- Dividend Yield
- XNET N/A
- ATAI N/A
- EPS Growth
- XNET N/A
- ATAI N/A
- EPS
- XNET 0.02
- ATAI N/A
- Revenue
- XNET $323,140,000.00
- ATAI $308,000.00
- Revenue This Year
- XNET N/A
- ATAI $65.58
- Revenue Next Year
- XNET N/A
- ATAI N/A
- P/E Ratio
- XNET $226.84
- ATAI N/A
- Revenue Growth
- XNET N/A
- ATAI N/A
- 52 Week Low
- XNET $1.46
- ATAI $1.03
- 52 Week High
- XNET $5.52
- ATAI $2.57
- Technical
- Relative Strength Index (RSI)
- XNET 59.27
- ATAI 49.02
- Support Level
- XNET $4.25
- ATAI $1.29
- Resistance Level
- XNET $4.54
- ATAI $1.44
- Average True Range (ATR)
- XNET 0.22
- ATAI 0.09
- MACD
- XNET 0.07
- ATAI -0.00
- Stochastic Oscillator
- XNET 86.85
- ATAI 50.00
About XNET Xunlei Limited
Xunlei Ltd is a cloud-based acceleration technology company in China. The company operates a powerful internet platform in China based on cloud computing to provide users with quick and easy access to digital media content through its products and services, Xunlei Accelerator, and cloud acceleration subscription services. It is increasingly extending into mobile devices in part through potentially pre-installed acceleration products in mobile phones Xunlei has developed various value-added services to meet a fuller spectrum of its users' digital media content access and consumption needs.
About ATAI ATAI Life Sciences N.V.
ATAI Life Sciences NV is a clinical-stage biopharmaceutical company on a mission to develop effective mental health treatments to transform patient outcomes. The company's pipeline of psychedelic-based therapies includes VLS-01 (buccal film DMT) for treatment-resistant depression (TRD) and EMP-01 (oral R-MDMA) for social anxiety disorder. It is also advancing a drug discovery program to identify novel, non-hallucinogenic 5-HT2AR agonists for TRD.